Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosing Dose-dependent exposure was observed with evidence of robust brain penetration Data supports potential advancement into Phase 2 for neurodegenerative diseases …